Why Is CytomX (CTMX) Stock Down 43% Today?

CytomX Therapeutics (NASDAQ:CTMX) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company.CytomX Therapeutics’ latest clinical trial update covers its Phase 1a study of CX-904, a cancer treatment in development. The company notes that the current results show a favorable safety profile and anti-cancer activity.However, diving into the data better explains why investors aren’t happy. Of the six pancreatic cancer patients able to be evaluated ...